Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

About this update from Ai, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d558e5317ef094556d38f0bfec206fff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zk5Nhro2O0BMZRzPEVQD_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d558e5317ef094556d38f0bfec206fff","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mokAlg901x2XFBmH_d1YPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d558e5317ef094556d38f0bfec206fff","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, January 11, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.","length":270,"tagName":"p"},{"type":"text","content":"Full Year 2025 Select, Preliminary, Unaudited Financial Results","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of ~$1.27 billion, representing ~83% growth year-over-year, including ~30% organic growth (excluding Ambry)","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Diagnostics revenue of ~$955 million, representing ~111% growth year-over-year, driven by Oncology volume growth of ~26% and Hereditary volume growth of ~29%","length":157,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data and applications revenue of ~$316 million, representing ~31% growth year-over-year, driven by ~38% growth in Insights (Data Licensing)","length":139,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":411,"olType":false},{"type":"text","content":"Fourth Quarter 2025 Select, Preliminary, Unaudited Financial Results","length":68,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth of ~29% and ...

More updates from Ai, Inc.